D
Darryl Falzarano
Researcher at Vaccine and Infectious Disease Organization
Publications - 81
Citations - 7271
Darryl Falzarano is an academic researcher from Vaccine and Infectious Disease Organization. The author has contributed to research in topics: Ebola virus & Medicine. The author has an hindex of 31, co-authored 66 publications receiving 5758 citations. Previous affiliations of Darryl Falzarano include Western University College of Veterinary Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure.
Masfique Mehedi,Masfique Mehedi,Thomas Hoenen,Shelly J. Robertson,Stacy M. Ricklefs,Michael A. Dolan,Travis Taylor,Darryl Falzarano,Hideki Ebihara,Stephen F. Porcella,Heinz Feldmann,Heinz Feldmann +11 more
TL;DR: This study reports for the first time that minigenomes containing the glycoprotein gene editing site can undergo RNA editing, thereby eliminating the requirement for a biosafety level 4 laboratory to study EBOV RNA editing.
Journal ArticleDOI
SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney.
Magen Ellen Francis,Magen Ellen Francis,Una Goncin,Andrea Kroeker,Cynthia Swan,Robyn Ralph,Robyn Ralph,Yao Lu,Athema L. Etzioni,Darryl Falzarano,Darryl Falzarano,Volker Gerdts,Steven Machtaler,Jason Kindrachuk,Jason Kindrachuk,Alyson A. Kelvin +15 more
TL;DR: This article investigated the host responses associated with infection in several major organ systems including the respiratory tract, the heart, and the kidneys after SARS-CoV-2 infection in Syrian hamsters.
Journal ArticleDOI
Vaccines for viral hemorrhagic fevers--progress and shortcomings
Darryl Falzarano,Heinz Feldmann +1 more
TL;DR: With a few exceptions, vaccines for viruses that cause hemorrhagic fever remain unavailable or lack well-documented efficacy and experimental vaccines for filoviruses and Lassa virus do exist but are hindered by a lack of financial interest and only partially or ill-defined correlates/mechanisms of protection that could be assessed in clinical trials.
Journal ArticleDOI
Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus
Darryl Falzarano,Darryl Falzarano,Darryl Falzarano,Friederike Feldmann,Friederike Feldmann,Allen Grolla,Anders Leung,Hideki Ebihara,Hideki Ebihara,James E. Strong,James E. Strong,Andrea Marzi,Andrea Marzi,Ayato Takada,Shane Jones,Jason Gren,Joan B. Geisbert,Steven M. Jones,Steven M. Jones,Thomas W. Geisbert,Heinz Feldmann,Heinz Feldmann,Heinz Feldmann +22 more
TL;DR: It is demonstrated that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.
Journal ArticleDOI
Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques.
Joseph Prescott,Darryl Falzarano,Emmie de Wit,Kath Hardcastle,Friederike Feldmann,Elaine Haddock,Dana P. Scott,Heinz Feldmann,Vincent J. Munster +8 more
TL;DR: The observation that the virus was less pathogenic in these animals suggests that disease has an immunopathogenic component and shows that inflammatory responses elicited by the virus contribute to disease.